{"doi":"10.3390/ijms25010440","title":"Current Insights and Future Directions in the Treatment of Heart Failure with Preserved Ejection Fraction","abstract":"<jats:p>Heart failure is a clinical syndrome associated with poor quality of life, substantial healthcare resource utilization, and premature mortality, in large part related to high rates of hospitalizations. The clinical manifestations of heart failure are similar regardless of the ejection fraction. Unlike heart failure with reduced ejection fraction, there are few therapeutic options for treating heart failure with preserved ejection fraction. Molecular therapies that have shown reduced mortality and morbidity in heart failure with reduced ejection have not been proven to be effective for patients with heart failure and preserved ejection fraction. The study of pathophysiological processes involved in the production of heart failure with preserved ejection fraction is the basis for identifying new therapeutic means. In this narrative review, we intend to synthesize the existing therapeutic means, but also those under research (metabolic and microRNA therapy) for the treatment of heart failure with preserved ejection fraction.</jats:p>","journal":"International Journal of Molecular Sciences","year":2023,"id":593060,"datarank":0.4775849266527884,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"self_citation_contribution":0.32958368660043297,"citation_network_contribution":0.1480012400523554,"self_endowment_contribution":0.32958368660043297,"citer_contribution":0.1480012400523554,"corpus_percentile":null,"corpus_rank":null,"citation_count":8,"citer_count":8,"citers_with_citation_signal":6,"citers_with_endowment":6,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1517817,"name":"Roxana-Daiana Lazar","orcid":null,"position":1,"is_corresponding":false},{"id":1517818,"name":"Alexandru Ruda","orcid":null,"position":2,"is_corresponding":false},{"id":1517819,"name":"Andreea Paula Buda","orcid":null,"position":3,"is_corresponding":false},{"id":1517820,"name":"Stefan Chiorescu","orcid":null,"position":4,"is_corresponding":false},{"id":1517821,"name":"Mihaela Mocan","orcid":"0000-0001-5906-8024","position":5,"is_corresponding":false},{"id":1517823,"name":"Dan Blendea","orcid":"0000-0002-4137-8582","position":6,"is_corresponding":false},{"id":1517816,"name":"Roxana Mihaela Chiorescu","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"Current Insights and Future Directions in the Treatment of Heart Failure with Preserved Ejection Fraction","abstract":"<jats:p>Heart failure is a clinical syndrome associated with poor quality of life, substantial healthcare resource utilization, and premature mortality, in large part related to high rates of hospitalizations. The clinical manifestations of heart failure are similar regardless of the ejection fraction. Unlike heart failure with reduced ejection fraction, there are few therapeutic options for treating heart failure with preserved ejection fraction. Molecular therapies that have shown reduced mortality and morbidity in heart failure with reduced ejection have not been proven to be effective for patients with heart failure and preserved ejection fraction. The study of pathophysiological processes involved in the production of heart failure with preserved ejection fraction is the basis for identifying new therapeutic means. In this narrative review, we intend to synthesize the existing therapeutic means, but also those under research (metabolic and microRNA therapy) for the treatment of heart failure with preserved ejection fraction.</jats:p>","is_dataset_classified":null,"base_score":2.1972245773362196,"endowment":2.1972245773362196,"datacite_reuse_total":0,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"38203612","pmcid":"PMC10778923","openalex_id":"https://openalex.org/W4390348475","authors":[],"funders":[{"funder_name":"project PDI-PFE-CDI 2021","grant_id":"40PFE/30.12.2021","title":null},{"funder_name":"internal grant of Iuliu Hatieganu University of Medicine, Cluj-Napoca,","grant_id":"internal grant of Iuliu Hatieganu University of Medicine, Cluj-Napoca, project number: 35158/17.12.2021,","title":null}],"total_grants":2,"fwci":1.4299,"citation_percentile":0.84539553,"influential_citations":0,"citation_trend":[{"year":2024,"count":3},{"year":2025,"count":4},{"year":2026,"count":1}],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://www.mdpi.com/1422-0067/25/1/440/pdf?version=1703775873","host_type":"journal"},{"url":"https://www.mdpi.com/1422-0067/25/1/440/pdf?version=1703775873","host_type":"publisher"},{"url":"https://www.mdpi.com/1422-0067/25/1/440/pdf","host_type":"publisher"},{"url":"https://doi.org/10.3390/ijms25010440","host_type":"journal"},{"url":"https://pubmed.ncbi.nlm.nih.gov/38203612","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/10778923","host_type":"repository"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10778923/pdf/ijms-25-00440.pdf","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC10778923","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC10778923?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":["Heart Failure Treatment and Management","Fuel Cells and Related Materials","Cardiovascular Function and Risk Factors","Humans","Quality of Life","Stroke Volume","Preservation, Biological","MicroRNAs","Heart Failure"],"mesh_terms":["Heart Failure","Humans","Preservation, Biological","Quality of Life","Stroke Volume","MicroRNAs"],"keywords":["Ejection fraction","Heart failure","Cardiology","Medicine","Internal medicine","Heart failure with preserved ejection fraction","Stroke volume","Intensive care medicine","Microarn","Melatonina","Serpina"],"sdg_mappings":[{"sdg_number":0,"sdg_label":"Good health and well-being"}],"linked_datasets":[],"clinical_trials":[],"software_tools":[],"database_accessions":[],"source":"live","citation_network_status":"fetched"},"created_at":"2026-07-26T16:58:21.204271Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}